Open Access Review Article Article ID: Allergy-3-119

    Inhibition of Interleukin-4 Signalling in the Treatment of Atopic Dermatitis and Allergic Asthma

    Neena Philips* and Mathew Samuel

    Atopic dermatitis and allergic asthma result from amplified immune response to environmental antigens, and allergic reactions from released IgE, histamine, leukotrienes and cytokines. Environmental antigens immune cells, of innate and adaptive immunity, to stimulate interleukin-4 (IL-4) mediated activation of Th2 cells and subsequent isotype switching of B cells to produce IgE antibodies, responsible for the clinical manifestation of atopic diseases. The IL-4 receptor alpha chain (IL4Rα), which mediates IL-4 signaling, is common to IL-4 and IL-13 receptors, with IL-13 being an associated cytokine in the allergic response. US Food and Drug Administration recently approved dupilumab, which blocks IL4Rα for the treatment of moderate to severe atopic dermatitis. In controlled trials, dupilumab counteracted the allergic response and the clinical symptoms of dermatitis and asthma, and dupilumab was more effective than other available treatments. The primary safety concern of dupilumab is conjunctivitis and its long-term safety, which is unknown.


    Published on: Jun 30, 2017 Pages: 19-21

    Full Text PDF Full Text HTML DOI: 10.17352/2455-8141.000019
    CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat


    Case Reports

    Pinterest on Allergy

    Help ? Google Reviews 11